Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
119
resultados
Última actualización
13/01/2026 [07:14:00]
Resultados 50 a 75 de 119
Resumen de: WO2026007297A1
A preparation method for a multifunctional biomimetic delivery platform efficiently crossing mucosal barriers and inducing mucosal immune enhancement and use thereof. The present invention relates to the technical field of biopharmaceuticals. On the basis of a biodegradable PLGA copolymer and a mixed lipid component, mucosal delivery carrier particles capable of simultaneously loading multiple antigens and immunostimulatory components are prepared by means of a double emulsion method, a rotary evaporation coating method, and an ultrasonic method. The PLGA nanoparticles are loading cores. The outer mixed lipid coating can fulfil the functions of mucus penetration, cell uptake, and thus immune activation.
Resumen de: WO2026007226A1
A nanoparticle loaded with an oral protein drug for the treatment of diabetes and a carrier. Raw materials of said nanoparticle comprise: a lipid molecule-modified zwitterionic polymer, a cationic lipid, a phospholipid, and cholesterol. The lipid molecule-modified zwitterionic polymer is composed of a lipid molecule and a polymer, wherein the lipid molecule is distearoyl phosphoethanolamine or dimyristoylglycerol, and the polymer is a poly(carboxybetaine) polymer, a poly(phosphobetaine) polymer, a poly(sulfobetaine) polymer, or poly-2-(N-oxide-N,N-diethylamino)ethyl methacrylate. Said nanoparticle significantly improves the oral bioavailability of the protein drug.
Resumen de: WO2026006906A1
A lipid nanoparticle delivery system; it has a cargo molecule; and a lipid nanoparticle encapsulating the cargo molecule, the lipid nanoparticle comprising ionizable lipids; helper lipids; sterol; and acid-containing lipids that are crosslinked; and methods of use thereof.
Resumen de: US2025025427A1
Compounds are provided having the following Formula (I):or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein G1, G2, R1, R2, R3, L1a, L1b, and L2 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Resumen de: GB2642389A
This disclosure provides the use of nanoparticles of self-assembled acidic molecular clusters (NP-AMCs) of ammonium salts to lower the pH of skin and underlying tissue of a human or other mammal as a means of stimulating the localized immune response to a wound.
Resumen de: MX2025011256A
The present application is directed, in general, to compositions comprising tolerizing immune modifying particles encapsulating Myasthenia Gravis (MG) associated antigens, methods of treating MG using tolerizing immune modifying nanoparticles encapsulating MG associated antigens, and a process for the preparation of tolerizing immune modifying nanoparticles encapsulating MG antigens.
Resumen de: EP4675006A2
A method of preparing a pharmaceutical composition is provided. The method includes the deposition of a metal oxide layer(s) followed byapplying a polymer layer(s). This produces a pharmaceutical composition comprising a drug containing core enclosed by one or more metal oxide materials and one more polymer materials.
Resumen de: EP4674857A2
The present disclosure relates to spheroidal organosiloxane submicron/nanoparticle comprising a network consisting of organosiloxane, and a process to make them.
Resumen de: EP4674412A1
The present invention relates to a microfluidic device for preparing lipid nanoparticles capable of delivering nucleic acids, and a method for preparing lipid nanoparticles using the same. Using the microfluidic device, lipid nanoparticles having a desired size can be prepared by adjusting the molar ratio of compositions and the Reynolds number.
Resumen de: CN120641393A
The present invention provides, in part, a diester and amide cationic lipid compound of formula (I): # imgabs0 # or a pharmaceutically acceptable salt thereof; a diester and amide cationic lipid compound of formula (II): # imgabs 1 # or a pharmaceutically acceptable salt thereof; a diester and amide cationic lipid compound of formula (III): # imgabs2 # (III), or a pharmaceutically acceptable salt thereof; and a diester and amide cationic lipid compound of formula (IV): # imgabs3 # or a pharmaceutically acceptable salt thereof. The compounds provided herein can be used to deliver and express mRNA and encoded proteins, for example, as components of liposomal delivery vehicles, and thus can be used to treat various diseases, disorders, and conditions, such as those associated with the lack of one or more proteins.
Resumen de: WO2024130086A1
Disclosed herein are lipid compounds and compositions comprising lipid compounds and methods of making and use thereof. The present disclosure also relates to methods for delivering an agent into a cell by introducing to the cell a therapeutically effective amount of the compositions, the lipid nanoparticles, the pharmaceutically acceptable compositions, or the hydrogel matrices disclosed herein. Also disclosed herein are methods for promoting wound repair in a subject by administering to the subject a therapeutically effective amount of the compositions, the lipid nanoparticles, the pharmaceutically acceptable compositions, or the hydrogel matrices disclosed herein.
Resumen de: CN120813339A
There is provided a compound represented by general formula (1) or an ionized form thereof for use in the preparation of lipid nanoparticles encapsulating therapeutic, prophylactic and/or biological agents: wherein NR1R2 is a group ionizable at pH from 3 to physiological pH; a comprises a linear aliphatic hydrocarbon, a branched aliphatic hydrocarbon and/or a cyclic hydrocarbon, optionally comprising one or more groups selected from the group consisting of-OH,-NR-,-O-,-O-CxH2x-O-, where x > = 1; and wherein R is H, an optionally substituted alkyl group, an optionally substituted alkenyl group, or an optionally substituted alkynyl group; r3, R4, R5, R6 and R7 are each independently H, an optionally substituted alkyl group, an optionally substituted alkenyl group or an optionally substituted alkynyl group; and R8 and R9 are each independently a hydrophobic group.
Resumen de: EP4674431A1
The present disclosure is a lipid nanoparticle including a composition including a protein selected from an antibody and an antibody fragment, a polymer, and a lipid, in which the polymer and the protein have opposite charges at a predetermined pH. The lipid nanoparticle preferably has a protein encapsulated therein. In addition, when the particle diameter of the lipid nanoparticles is measured, the peak top of the particle diameter distribution is preferably at 80 nm to 120 nm.
Resumen de: AU2024229078A1
The present invention relates to nanocomplexes (NCs) comprising a polysaccharide nanoparticle (NP) and a hormone selected from insulin, glucagon, or glucagon-like protein-1, and uses thereof for reducing the blood glucose level, in particular, for the treatment of diabetes.
Resumen de: MX2025009920A
The present application discloses compositions comprising nanoparticles of vitamin K2, and their methods of use.
Resumen de: MX2025014185A
Provided is a polymer comprising a structure of Formula (1): (1) and a method of preparing said polymer. Also provided is a composition comprising the polymer and a nucleic acid and/or polypeptide, and a method of delivering a nucleic acid and/or polypeptide to a cell.
Resumen de: MX2025014047A
This application disclose a polynucleic acid molecule conjugate comprising an antibody or binding fragment thereof conjugated to a polynucleic acid molecule that hybridizes to a target sequence of an atrogene; wherein the polynucleic acid molecule comprises at least one 2' modified nucleotide, at least one modified intemucleotide linkage, or at least one inverted abasic moiety; and wherein the polynucleic acid molecule conjugate mediates RNA interference against the atrogene, thereby treating muscle atrophy or myotonic dystrophy in a subject. In a certain embodiment, atrogene comprises atrogin-1 gene (FBXO32), MuRF1 gene (TRIA63), FOXO1, FOXO3, or MSTN.
Resumen de: MX2025012226A
Disclosed herein is a polysialic acid (PSA)-polymer conjugate compound represented by the structural formula (I): or a pharmaceutically acceptable salt thereof, wherein P is a poly(lactide-co-glycolide)-poly(ethylene glycol) copolymer (PLGA-PEG) and p is an integer from 4 to 200, nanoparticles comprising same, and methods of treating ophthalmic diseases using same.
Resumen de: MX2025013817A
The present disclosure relates to a process for the preparation of tolerizing immune modifying nanoparticles encapsulating antigens associated with primary biliary cholangitis (PBC), compositions comprising the particles and use thereof for the treatment of PBC.
Resumen de: MX2025010922A
Provided is an anti-Claudin18.2 nanobody or a binding fragment thereof. The antibody has good specificity, and immune effector cells targeting Claudin18.2 which are prepared from the antibody show a good therapeutic effect in treating or ameliorating diseases having positive expression of Claudin18.2.
Resumen de: EP4674856A2
The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
Resumen de: CN121265555A
本发明属于硒纳米颗粒复合材料技术领域，具体涉及一种巴利森苷修饰的硒纳米颗粒及其制备方法和应用。本发明提供的巴利森苷修饰的硒纳米颗粒，具有核壳结构，包括硒纳米颗粒和包覆在硒纳米颗粒表面的巴利森苷。所述巴利森苷修饰的硒纳米颗粒中巴利森苷分子对葡萄糖转运蛋白‑1具有亲和力，表现出良好的靶向潜力，并具有良好的抗氧化效果。超小剂量的巴利森苷修饰的硒纳米颗粒可通过抗氧化活性缓解过氧化氢造成的不同程度细胞损伤，表现出良好的肝保护效果，可作为一种高效保肝护肝体系。
Resumen de: AU2023394992A1
The present invention relates to a messenger RNA (mRNA)-based immunogenic composition that is capable of inducing a mammalian cell to produce an influenza virus-like particle (VLP). The immunogenic composition comprises one or more mRNAs encoding an influenza virus matrix 1 (M1) protein and one or more influenza virus hemagglutinin (HA) proteins and/or one or more influenza virus neuraminidase (NA) proteins.
Resumen de: CN121271804A
本发明涉及一种条件激活型免疫细胞及其组合物和应用。具体地，本发明提供一种偶联纳米颗粒的免疫细胞，免疫细胞表达嵌合抗原受体，所述免疫细胞通过连接子与纳米颗粒偶联，其中，所述连接子包含第一肽段，所述第一肽段包含一个或多个配体诱导型蛋白酶水解裂解位点。本发明提供一种定点“开关型”表达嵌合抗原受体的免疫细胞，能够实现对免疫细胞的精准调控，可有效降低靶向脱瘤毒性，进而降低毒副作用，极大地提高了安全性。
Nº publicación: CN121265552A 06/01/2026
Solicitante:
中国医学科学院药物研究所
Resumen de: CN121265552A
本发明属于医药技术领域，公开一种负载银纳米粒的脂质体纳米制剂及其制备和应用。本发明采用薄膜分散法制得包载银纳米粒的纳米颗粒。本发明的仿生纳米药物有助于解决抗菌药物银纳米粒细菌摄取效率低的问题，提高药物杀灭瘤内菌的能力，进而提高抗肿瘤效果。制备工艺简单、成本低、稳定性好、可重复性高。
BOPI
Sede Electrónica
